Adolescents With Type 1 Diabetes Using Dapagliflozin as an Adjunct-to-Insulin: Perspectives on Experiences of Clinical Trial Participation
Authors' conclusion
Adolescents in the ATTEMPT study did not express a higher burden of daily diabetes management with adjunct-to-insulin therapy. Findings support the value of a strong research team to ensure communication with adolescents with attention to ethical considerations around recruitment, consent, and participation. Adolescent perspectives in efficacy studies of new treatments in type 1 diabetes can optimize trial designs, research validity, and inform outcome findings.
Study context
- Population
- Adolescents aged 12 to 17 years with T1D taking dapagliflozin (SGLT2i) as adjunct-to-insulin in the ATTEMPT trial13 males
- Participants
- 24 adolescents
- Outcome
- Adolescent experiences of trial participation
Methodological detailsembedded experimental mixed method design, qualitative description, semi-structured interviews, content and thematic analysis
- Embedded experimental mixed method design
- Qualitative description
- Semi-structured interviews
- Content and thematic analysis
Main finding
As reported in the abstract
- Decision-making about trial participation was multifaceted
- Adhering to an SGLT2i adjunctive medication was non-burdensome
- Trial participation had unexpected informative benefits, incl. improved self-management skills and ketone measurement awareness
- 3 themes
Original publication
Adolescents With Type 1 Diabetes Using Dapagliflozin as an Adjunct-to-Insulin: Perspectives on Experiences of Clinical Trial Participation. Endocr Pract. Published 31 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →